ArticleCureus2025
Olanzapine-Induced Rhabdomyolysis and Hyponatremia: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olanzapine, a second-generation antipsychotic, is generally well tolerated but can rarely be associated with serious complications such as rhabdomyolysis and hyponatremia. We report the case of a woman in her early forties with a 15-year history of paranoid schizophrenia who developed bilateral foot drop and seizures in the context of severe hyponatremia and markedly elevated creatine phosphokinase (CPK) levels. Symptoms arose after olanzapine dose escalation from 10 to 20 mg daily to address difficult psychiatric symptoms. Magnetic resonance imaging (MRI) showed diffuse T2 hyperintensity in calf muscles, and nerve conduction studies revealed bilateral common peroneal neurapraxia. The presentation was attributed to olanzapine-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH) and rhabdomyolysis. Both olanzapine and Lurasidone were stopped on admission; sequential re-challenge identified olanzapine as the probable causative agent. This case highlights the importance of early recognition of muscle symptoms and electrolyte disturbances in patients on antipsychotics, particularly following dose adjustments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.